We are Ferring International PharmaScience Center (IPC), in Denmark - the principal development organisation of Ferring Pharmaceuticals worldwide.
Wednesday, February 5, 2014
New paper indicates a potential fifty-percent reduction in cardiac events for prostate cancer patients with pre-existing cardiovascular disease when treated with FIRMAGON® (degarelix) compared to LHRH agonists
Friday, November 1, 2013
Ferring Pharmaceuticals appoints Alex Chang Senior Vice President, Asia Pacific